Retatrutide Research Guide

Retatrutide is an investigational triple hormone receptor agonist (GLP-1, GIP, and glucagon) that has produced some of the largest weight-loss results in early-phase trials.

Pharmacokinetics

Retatrutide has an estimated half-life of roughly 6 days, supporting weekly dosing. Bioavailability data are limited; the values in our dataset are estimated from early trial disclosures.

Why add glucagon?

Glucagon receptor activity drives additional hepatic fat oxidation and energy expenditure, which may explain the magnitude of weight loss beyond what dual agonism achieves.

Cautious interpretation

Because retatrutide’s parameters are partly estimated, our simple-model caveats apply doubly here. Use the curve to understand relative accumulation, not absolute blood levels.